ATYPICAL TERATOID/RHABDOID TUMOR
Clinical trials for ATYPICAL TERATOID/RHABDOID TUMOR explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL TERATOID/RHABDOID TUMOR trials appear
Sign up with your email to follow new studies for ATYPICAL TERATOID/RHABDOID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells target Kids' brain tumors in pioneering trial
Disease control OngoingThis early-stage study is testing a new treatment for children and young adults whose brain or spinal cord tumors have come back or haven't responded to standard therapies. Doctors collect the patient's own immune cells, modify them in a lab to recognize and attack cancer cells, …
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for kids with Ultra-Rare, aggressive cancers
Disease control OngoingThis study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for kids with devastating rare cancers
Disease control OngoingThis study is testing a drug called alisertib for children and young adults with rare, aggressive tumors called AT/RT and MRT. It is for patients whose cancer has come back and for those newly diagnosed. The goal is to see if adding alisertib to standard treatments helps control …
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New immune attack on rare, aggressive cancers
Disease control OngoingThis study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC